Polyether F127 Diacrylate

Synonyms: F127DA
Polyether F127 Diacrylate (F127DA) 是丙烯酰化的聚乙二醇-聚丙二醇-聚乙二醇三嵌段共聚物,在紫外及可见光下经光引发剂作用可快速交联固化成胶,具有优异的热致凝胶特性和良好的生物安全性,可上调整合素 (Integrin)-FAK 通路,增加胶原蛋白生成、升高 COL-1/SCX 蛋白表达水平以及基因表达水平,促进牙周膜干细胞的成纤维分化,并可促进大鼠延迟再植牙模型中的牙周膜再生、减少异常愈合,促进大鼠骨关节炎模型中的功能性骨软骨再生,同时对脂肪组织存活有支持作用,使其适用于乳房重建应用,可用于牙周膜损伤、乳腺缺损及骨关节炎的相关研究。
聚醚F127二丙烯酸酯
产品编号: MS-Y59012
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Polyether F127 Diacrylate (F127DA) 是丙烯酰化的聚乙二醇-聚丙二醇-聚乙二醇三嵌段共聚物,在紫外及可见光下经光引发剂作用可快速交联固化成胶,具有优异的热致凝胶特性和良好的生物安全性,可上调整合素 (Integrin)-FAK 通路,增加胶原蛋白生成、升高 COL-1/SCX 蛋白表达水平以及基因表达水平,促进牙周膜干细胞的成纤维分化,并可促进大鼠延迟再植牙模型中的牙周膜再生、减少异常愈合,促进大鼠骨关节炎模型中的功能性骨软骨再生,同时对脂肪组织存活有支持作用,使其适用于乳房重建应用,可用于牙周膜损伤、乳腺缺损及骨关节炎的相关研究。

生物实验数据

生物活性 Polyether F127 Diacrylate (F127DA) is an acrylated polyethylene glycol-polypropylene glycol-polyethylene glycol triblock copolymer that rapidly crosslinks and solidifies into a gel under UV and visible light in the presence of a photoinitiator, possesses excellent thermogelation properties and good biosafety, upregulates the Integrin-FAK pathway, increases collagen production, elevates COL-1/SCX protein expression levels as well as gene expression levels, promotes the fibroblastic differentiation of periodontal ligament stem cells, promotes periodontal ligament regeneration and reduces abnormal healing in a rat delayed tooth replantation model, promotes functional osteochondral regeneration in a rat osteoarthritis model, and supports adipose tissue survival, making it suitable for breast reconstruction applications, and can be used for research related to periodontal ligament injury, breast defects, and osteoarthritis.
体外研究
(In Vitro)

Polyether F127 Diacrylate (5-20% wt/vol) 水凝胶与 hPDLSCs 具有良好的细胞相容性,在 7 天内可维持细胞高存活率 (>90%) 并支持细胞增殖,其中 F127DA-5 可促进最高的增殖速率。
Polyether F127 Diacrylate (5-20% wt/vol) 水凝胶在静态条件下对 hPDLSC 的成纤维分化无差异化影响;但在细胞力学加载条件 (0-120 kPa, 1 Hz, 1 h day-1 for 7 days) 下,F127DA-5 通过上调整合素-FAK 通路及细胞骨架重排显著促进 hPDLSC 的成纤维分化,表现为胶原蛋白生成增加、COL-1/SCX 蛋白表达水平升高以及 COL-1/SCX 基因表达水平上调。

Cell Viability Assay

Cell Line: human periodontal ligament stem cells (hPDLSCs)
Concentration: 5% wt/vol (F127DA-5); 10% wt/vol (F127DA-10); 20% wt/vol (F127DA-20)
Incubation Time: 24 h (morphology); 1, 3, 7 days (viability/proliferation)
Result: Adhered to all F127DA hydrogel surfaces with uniform round/compact morphology, with no significant difference in number of round cells across groups.
Showed >90% cell viability for all groups at 1, 3, 7 days.
Exhibited increasing proliferation over time, with F127DA-5 having significantly higher optical density (OD) values at 450 nm than F127DA-20 on days 3 and 7.

Cell Differentiation Assay

Cell Line: human periodontal ligament stem cells (hPDLSCs)
Concentration: 5% wt/vol (F127DA-5); 10% wt/vol (F127DA-10); 20% wt/vol (F127DA-20); 0-120 kPa (cytomechanical loading pressure)
Incubation Time: 7 days (static culture); 7 days (cytomechanical loading, 1 Hz, 1 h day-1)
Result: Showed no significant differences in collagen concentration, COL-1/SCX immunofluorescence intensity, or COL-1/SCX gene expression across F127DA groups under static conditions.
Exhibited significantly higher collagen concentration, COL-1/SCX immunofluorescence intensity, and COL-1/SCX gene expression in F127DA-5 compared to F127DA-10 and F127DA-20 under cytomechanical loading.
体内研究
(In Vivo)

Polyether F127 Diacrylate (5-20% wt/vol; subcutaneous; single implant) 在雄性 C57BL/6 小鼠皮下植入后 2 周时表现出体内生物相容性,无全身毒性或局部不良组织反应,呈现缓慢的体内生物降解,同时在植入部位保持结构存在至少 2 周。
Polyether F127 Diacrylate (5-20% wt/vol; local coating on root surfaces; single dose) 中的 F127DA-5 水凝胶可显著促进大鼠延迟再植牙模型中的牙周膜再生,并减少异常愈合 (牙根吸收和牙粘连)。
Polyether F127 Diacrylate (15% (w/v); subcutaneous; single implantation) 和 3% PEGDA 组成的 3D 打印多孔支架,在裸鼠皮下植入后表现出良好的体内生物相容性、结构稳定性以及对脂肪组织存活的支持作用,使其适用于乳房重建应用。
Polyether F127 Diacrylate (15% (w/v); intra-articular; single injection; in situ photocrosslinking with 405 nm light) 与 10% (w/v) GelMA 复合,负载 30 μM KGN 和 200 ng/mL TGF-β 可显著促进大鼠骨关节炎模型中的功能性骨软骨再生。

Animal Model: C57BL/6 (male, 7-8 weeks old)
Dosage: 5%, 10%, 20% wt/vol (F127DA-5, F127DA-10, F127DA-20 hydrogels)
Administration: subcutaneous; single implant
Result: Showed no signs of infection at surgical sites; all animals survived.
Demonstrated immune cell infiltration around implants, no fibrous tissue formation at 2 weeks, and newly formed blood vessels in transplanted areas.
Detected no tissue damage, inflammation, hemorrhage, or necrosis in heart, lung, liver, kidney, or spleen tissues.\nDegraded over time but remained at implantation sites for 2 weeks post-transplantation.
Animal Model: Sprague-Dawley (male, 7-8 weeks old, 180-250 g, periodontal ligament injury model via delayed replantation of avulsed incisor)
Dosage: 5%, 10%, 20% wt/vol (F127DA-5, F127DA-10, F127DA-20 hydrogels; single 20 μL root coating)
Administration: local coating on root surfaces; single dose; prior to replantation
Result: Exhibited the highest area of newly formed PDL tissue in the F127DA-5 group, with significantly greater PDL length and significantly reduced root resorption and ankylosis compared to the F127DA-10 group.
Showed reduced root resorption in the F127DA-20 group compared to the F127DA-10 group.
Formed dense, perpendicular collagen fiber bundles resembling native PDLs between roots and alveolar bone in the F127DA-5 group, with minimal inflammation, root resorption, and ankylosis.
Demonstrated frequent inflammation, replacement root resorption, and ankylosis in the F127DA-10 and F127DA-20 groups.
Showed the highest expression levels of PDL fibrogenic differentiation markers COL-1 and SCX in newly formed tissues in the F127DA-5 group.
Animal Model: nude mice (female, 8 weeks old)
Dosage: 15% (w/v) (formulated with 3% PEGDA, 0.25% LAP, and UV absorber)
Administration: subcutaneous; single implantation
Result: Showed visible blood vessels on scaffold surface by 14 days post-implantation.
Developed an obvious fat mass with no observed foreign body reaction by 28 days post-implantation.
Revealed clearly visible round or multilobular adipose tissue structures within and around the scaffold at both 14 and 28 days via histological HE staining.
Maintained no significant degradation over 28 days, with stable weight, width, and length measurements throughout the observation period.
Exhibited a compression modulus of (17.12) kPa, close to that of commercial breast prostheses and within the range of natural breast tissue (2-66 kPa).
Animal Model: Sprague-Dawley (SD) (8-week-old male; osteoarthritis model via medial meniscus defect + 2 weeks rearing + femur osteochondral defect creation)
Dosage: 15% (w/v) (combined with 10% (w/v) GelMA, loaded with 30 μM KGN and 200 ng/mL TGF-β)
Administration: intra-articular; single injection; in situ photocrosslinking with 405 nm light
Result: Promoted significant functional cartilage regeneration with more intact glycosaminoglycan-rich matrix compared to control groups.
Demonstrated effective repair of osteochondral defect structure, with more organized tissue architecture compared to control groups.
Reached COL II fluorescence intensity of 19.28 a.u., significantly higher than defect and single-drug groups.
Achieved the smoothest subchondral bone surface with the least damage, with coronal plane CT intensity of 147.1, sagittal plane intensity of 133.2, and transversal plane intensity of 156.3, all significantly higher than control groups.
性状 固体
颜色 White to off-white

化学信息

别名 F127DA

储存&溶解度

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础